This investigator-initiated Phase II trial provided the rationale to initiate the STELLAR-305 Phase II/III study investigating the efficacy of the TKI zanzalintinib in combination with P in PD-L1-positive R/M HNSCC patients (NCT06082167). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.